Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments, consumables
and platform-technology solutions to the life sciences and other industries,
was recently covered in a research report by Zacks Small Cap Research, a
division of Zacks Investment Research. Among other highlights, Zacks maintained
its $4.44 share price target on shares of PBIO. An article discussing the
company reads, “The Zacks report (http://ibn.fm/z1W3H)
points to demand that ‘is expected to accelerate starting in 2020,’ which
nonetheless follows many years of consistent yearly revenue increases by PBIO.
The company itself is standing by its stated anticipation of doubling revenue
in 2020, due to expected sales of their soon-to-be-released $200,000 BaroShear
K45 systems. These new instrument systems utilize PBI’s proprietary Ultra Shear
Technology(TM) (UST) platform to effectively produce high-quality, long-term
stable, water-soluble nanoemulsions of CBD oil (http://ibn.fm/PFora).”
To view the full article, visit http://ibn.fm/vSmuE
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control bio-molecular
interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus
is in the development of PCT-based products for biomarker and target discovery,
drug design and development, biotherapeutics characterization and quality
control, soil and plant biology, forensics and counter-bioterror applications.
Additionally, major new market opportunities have emerged in the use of its
pressure-based technologies in the following areas: (1) the use of its recently
acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to
allow entry into the biopharma contract services sector, and (2) the use of its
recently patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality,
homogenized, extended shelf-life or room-temperature, stable low-acid liquid
foods that cannot be effectively preserved using existing nonthermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.htm
